Skip to content
See the World Through ScienceA project of ALLATRA

Light and Sound Therapy Did Not Slow Alzheimer's Decline in a Yearlong Trial

Science

Republish this story

Our work is licensed under Creative Commons BY-NC 4.0. You may republish this piece for free — with credit to ALLATRA Media and a link to the original, unedited beyond length trims, and not for commercial use.

Read the full license

An illustration of two brain cross-sections side by side, a healthy one at left and one with severe Alzheimer's disease at right, its cortex and hippocampus shrunken and its ventricles enlarged.
At left a healthy cross-section, at right the late stage, the cortex and hippocampus wasted and the ventricles widened. The trial enrolled 673 people at mild to moderate stages (illustrative)."Alzheimer's disease brain comparison" by derivative work: Garrondo (talk) SEVERESLICE_HIGH.JPG: ADEAR: "Alzheimer's Disease Education and Referral Center, a service of the National Institute on Aging." PRECLINICALSLICE_HIGH.JPG: ADEAR: "Alzheimer's Disease Education and Referral Center, a service of the National Institute on Aging.", via Wikimedia Commons, Public domain

Cognito's Spectris, a headset that aims to treat Alzheimer's disease with flickering light and rhythmic sound, failed the main test of a 673-participant trial, the company announced Nov. 16, 2026. The company said that in the full group of patients with mild-to-moderate Alzheimer's disease, a year of daily use left them no better off than a sham device, and that the trial's secondary measures showed no significant differences either.

The device pairs goggles with headphones and is worn for an hour a day at home. Cognito says the light and sound are timed to drive brain activity at 40 Hz, a rhythm it links to attention, perception and memory.

The company's own release leads on a different result. Among the 395 participants who entered with milder disease, a subgroup defined in advance, Cognito reported 56% slowing of decline on a measure of daily function and 47% on a measure of cognition and function. It marks both figures as nominal, meaning they are not corrected for the number of measures tested. Chief Executive Christian Howell said in the release, "We had hoped to see an effect across that overall population, and we did not." Cognito intends to seek FDA authorization for use in early symptomatic Alzheimer's disease.

Nature's news desk covered the conference presentation independently and reported that active-device users in the mild group declined 41.6% more slowly over the year than sham users.

"The trial was negative," Eric McDade, a neurologist at Washington University School of Medicine in St. Louis who was not involved in the study, told Nature. For Rob Howard, a psychiatrist at University College London who specializes in dementia, the subgroup data is exploratory rather than persuasive proof of effect. "If this was a drug, such a clear failure would mean that a company would not proceed to seek regulatory approval," Howard said. He noted that earlier trials have not succeeded either; a smaller study of the device failed in 2024.

Cognito reported no unanticipated adverse device effects in either arm. Spectris AD has not been authorized by the FDA, and the release states that its safety and effectiveness have not been established.

Sources

Spot an error?

Spot an error?

Report an error

Spotted a mistake on this page? Tell us what's wrong and our editors will take a look.

What kind of problem?

Only if you'd like us to be able to follow up. We won't use it for anything else.

We correct mistakes openly. Select any text to flag it. Fixes are logged under our Corrections Policy.

Report an error

Reporting on

Light and Sound Therapy Did Not Slow Alzheimer's Decline in a Yearlong Trial

What kind of problem?

Only if you'd like us to be able to follow up. We won't use it for anything else.

We read every report. Corrections are logged publicly.